


GROWING HOPE:

Using Mini-Tumors to Explore New Combination Treatments for Ovarian Cancer

By Emily Tomas, PhD



Source: [MedlinePlus](#)

Ovarian cancer is one of the deadliest cancers that affects women. Most patients are diagnosed after the disease has already spread throughout the abdomen, making treatment more difficult. Although surgery and chemotherapy can be effective at first, the cancer often returns and sometimes becomes resistant to chemotherapy. When this happens, treatment options become limited and survival rates remain low.

Researchers are constantly searching for new ways to improve outcomes for patients with ovarian cancer. One promising group of targeted drugs is called PARP inhibitors. They work by targeting cancer cells that are unable to properly repair their damaged DNA. Two PARP inhibitors are already approved for certain ovarian cancer patients. Olaparib is approved for patients with mutations in Breast Cancer gene 1 or 2 (*BRCA1* or *BRCA2*), which cause a disruption in DNA repair; whereas Niraparib is approved for all ovarian cancer patients whose cancer has recurred.

In this study, researchers decided to ask an important question: *Are PARP inhibitors more effective when combined with chemotherapy, or when administered before chemotherapy rather than after?* To answer this question, a research team investigated [how ovarian cancer cells respond to different treatment combinations](#) and treatment schedules. They determined whether combining chemotherapy with the two approved PARP inhibitors could improve cancer cell killing. They also wanted to investigate whether the order of treatment mattered.

To answer these questions, the team used ovarian cancer cells that were originally developed from fluid collected from ovarian cancer patients. Because every patient's tumor is different, the researchers studied several distinct ovarian cancer samples to capture the diversity seen in real patients.

Another important aspect of this study was to model ovarian cancer cells more accurately using two advanced three-dimensional laboratory systems. The first model, called a “spheroid”, mimics the clusters of cancer cells that spread throughout the abdomen during ovarian cancer metastasis. The second model, called an “organoid”, resembles a miniature version of a patient's tumor. Organoids preserve many of the characteristics found in tumors growing inside the body and are becoming valuable tools for testing new therapies. Both systems are unique in their ability to show differing characteristics of cancerous cells as they spread and grow in the body.

The researchers first measured how sensitive each cell line was to carboplatin (chemotherapy drug), Olaparib (PARP inhibitor), and Niraparib (PARP inhibitor) individually. They then tested different treatment strategies to see which had the greatest reduction in cancer cell survival. This includes:

- Chemotherapy alone
- A PARP inhibitor alone
- Chemotherapy combined with a PARP inhibitor
- A PARP inhibitor followed by chemotherapy
- Chemotherapy followed by a PARP inhibitor

The first major finding was that ovarian cancer cells responded very differently to treatment. Some cells were highly sensitive to chemotherapy, while others were more resistant. Similar differences were observed with the PARP inhibitors. This highlights the fact that ovarian cancer is not a single disease, and each patient's tumor can respond differently to therapy.

The researchers also found that Niraparib generally killed cancer cells more effectively than Olaparib. One particular cell line that carried a *BRCA1* mutation was especially sensitive to both PARP inhibitors, which was expected because BRCA-related cancers often depend heavily on DNA repair.

The team then compared drug responses in spheroids and organoids. Interestingly, the same cancer cells sometimes responded differently depending on which model was used. This finding suggests that three-dimensional models provide a more realistic picture of how tumors behave and may better predict patient responses than traditional laboratory cultures. Again, this means that patients may respond differently based on the extent to which their disease has spread.

The most surprising results came from the combination treatment experiments. The researchers expected that combining chemotherapy with a PARP inhibitor would increase cancer cell death. Instead, they found that most combinations performed no better than chemotherapy alone. In many cases, adding a PARP inhibitor did not significantly improve treatment effectiveness. Further analyses suggested that some drug combinations might even interfere with one another under certain conditions. These findings indicate that simply adding more drugs does not always produce better results.

Finally, the researchers tested whether treatment order could influence effectiveness. For most ovarian cancer models, changing the order of treatment produced little difference. However, one important exception emerged. A *BRCA1*-mutated sample responded better when a PARP inhibitor was given before chemotherapy, and showed greater cancer cell killing than chemotherapy alone. Although this effect was observed in only one sample, it suggests that some patients may benefit from receiving PARP inhibitors earlier in their treatment.

Overall, this study demonstrates *the complexity of treating ovarian cancer*. Different tumors can respond very differently to the same drugs, making personalized treatment approaches increasingly important. The findings suggest that combining chemotherapy with PARP inhibitors may not provide additional benefits for most patients. However, treatment timing could matter, where giving a PARP inhibitor before chemotherapy may improve treatment effectiveness.

The study also highlights the value of “personalized medicine” in treating cancer patients. In an ideal world, patients would provide a sample of their cancer and researchers would use these three-dimensional models (“spheroids” and “organoids”) in a laboratory environment to learn about their unique cancer. The results could then be used to help doctors match patients with therapies most likely to work for their specific cancer.

Looking ahead, larger studies will be needed to identify which patients are most likely to benefit from alternative treatment schedules. But ultimately, this research study brings us one step closer to more effective and individualized treatments for all ovarian cancer patients.

Original Article: Tomas, E. J., Davis, J., Ramos Valdes, Y., & Shepherd, T. G. (2026). Evaluating carboplatin and PARP inhibitor combination efficacy using high-grade serous carcinoma spheroids and organoids. *Cancer Biology & Therapy*, 27(1). <https://doi.org/10.1080/15384047.2025.2611602>